As the the year comes to end, there is still a steady flow of interesting news coming from small cap biotech stocks like Organovo Holdings Inc (NYSEMKT: ONVO), Advanced Cell Technology, Inc (OTCMKTS: ACTC) and TNI BioTech (OTCMKTS: TNIB)�plus still largely private biotech companies like Genocea Biosciences (NASDAQ: GNCA), Retrophin (OTCMKTS: RTRX), Auspex Pharmaceuticals (NASDAQ: ASPX) and GlycoMimetics (NASDAQ: GLYC) who have filed to become the next potentially hot biotech IPOs���presumably some time early�next year. Just consider the following biotech news:
Organovo Holdings Inc Wants to Use 3D Printing to Print a Liver Next Year. ComputerWorld has reported that San Diego-based small cap bio-printing company Organovo Holdings is now expecting to unveil the world's first printed organ, a human liver, next year. However, the article is quick to add that Organovo Holdings is only�planning to print liver tissue�for research use only and that the tissue will be used in the laboratory for medical studies and drug research. Nevertheless, there�are about 120,000 people on the organ waiting list in the US and those who do receive organs face the possibility of rejection���something that would not happen if a patient�� own stem cells are used to create a new organ. But research into whole organ regeneration currently receives less than $500 million in funding a year in the US verses�$5 billion for cancer research and $2.8 billion for HIV and AIDS. Organovo Holdings is one of this year�� best performing stocks because�its up 248.1% since the start of the year and up 483.9% since February 2012.Top 10 Railroad Stocks To Invest In Right Now: NK Lukoil OAO (LKOH)
NK Lukoil OAO (Neftyanaya Kompaniya LUKOIL OAO or NK LUKOIL OJSC) is a Russia-based integrated oil and gas company. The Company is engaged in the business of oil exploration, production, refining, marketing and distribution. It is an owner of refineries, gas processing, petrochemical plants and gas stations network located in Russia, Eastern and Western Europe, as well as Africa. The Company�� petroleum products are sold in the Russian Federation, the Commonwealth of Independent States (CIS) countries, Eastern and Western Europe, Asia and the United States. NK Lukoil OAO operates through numerous subsidiaries and affiliated companies. In April 2013, the Company acquired a 100% of Samara-Nafta ZAO and completed acquisition of CJSC Kama-Oil. In June 2013, it sold a 99.57% stake in Lukoil Odes'kyi NPZ PAT. The Company�� major shareholder is NKO ZAO NRD with a stake of 91.60%. In December 2013, it consolidated a 100% stake in ISAB Srl. Advisors' Opinion:- [By Maria Levitov]
Russia�� Micex Index extended a five-day drop to 3.4 percent, led by OAO Lukoil (LKOH) and OAO Gazprom. Ukraine�� dollar-denominated bonds gained, sending yields to the lowest this week, as President Viktor Yanukovych announced possible investments from China. The PX Index slid to a seven-week low in Prague as Vienna Insurance Group AG plunged 4.2 percent.
- [By Rajhkumar K Shaaw]
Russian stocks rose as oil, the nation�� main export earner, climbed. OAO Lukoil (LKOH) gained for the first time this week. Benchmark gauges in Hungary and Turkey also advanced. Tofas Turk Otomobil Fabrikasi AS, the Turkish carmaker part-owned by Fiat SpA, climbed for a second day on bets plans to roll out a new vehicle will boost revenue from exports.
Top Electric Utility Stocks To Buy Right Now: Recon Technology Ltd.(RCON)
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People?s Republic of China. The company offers equipment, tools, and other hardware related to oilfield production and management; and develop and sell industrial automation control and information solutions. Its oil and gas production and transportation equipment comprise heating furnaces, burners, and separators. Recon Technology, Ltd.?s oil and gas development tools and equipment include packers of fracturing, production packers, and water injection packers; and oil and gas production increasing techniques consist of fissure shaper technique to increase perforation depth, sand prevention in oil and water well technique, water locating and plugging technique, fracture acidizing technique, and electronic broken-down service. Its automation systems and services comprise pumping unit controllers that monitors the pumping units and co llects data for load, pressure, voltage, startup, and shutdown control; RTU for monitoring natural gas wells and collecting gas well pressure data; wireless dynamometer and wireless pressure gauge; electric multi-way valve for oilfield metering station flow control; and natural gas flow computer system to measure the flow. The company?s automation systems and services also consist of Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil, and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead area and measure station area; and technique service for digital oilfield transformation. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By James E. Brumley]
Anybody who was lucky enough to get into a Recon Technology, Ltd. (NASDAQ:RCON) position before October 7th, then congratulations - you're up big-time. Now get out. Instead, a better use of that capital is Mitek Systems, Inc. (NASDAQ:MITK). While RCON is overbought and ripe for a pullback, MITK is itching to stage a breakout.
Top Electric Utility Stocks To Buy Right Now: ONYX Pharmaceuticals Inc.(ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Ben Levisohn]
The big news in biotech this week has been the purchase of Onyx Pharmaceuticals (ONXX) by Amgen (AMGN). Amgen popped 7.8% after the purchase was announced, in part for the cheap(er) price it paid, but also for the drugs that would be added to its pipeline.
ReutersNow Societe Generale considers the impact of biologic drugs on the stock prices of pharmaceutical companies. Analyst Stephen McGarry writes:
We have previously argued that there is likely to be limited genericisation of complex biologics due to difficult ies in their manufacture and the upfront at-risk capex, among other things, and we repeat those arguments in this report. If this thesis is borne out over the long term, then pharmaceutical companies whose R&D pipelines contain large numbers of difficult-to-copy biologics should be rewarded with higher valuations, since revenues and profits should be more sustainable for those drugs in development that do reach commercialisation. Further, if pharma companies continue to expand the biologics component of their R&D pipelines, they should deserve even higher valuations.
The European pharmaceutical stocks that don’t reflect the potential of biologics yet include Novartis (NVS) and Sanofi (SNY), McGarry says.
Novartis has dropped 1.3% to $74.15 today, while Sanofi has fallen 2.4% to $49.57.
- [By Ben Levisohn]
After weeks of speculation, Amgen’s (AMGN) purchase of Onyx Pharmaceuticals (ONXX) looks like a done deal. The Wall Street Journal has the details:
- [By Sean Williams]
The newest treatment on the block is Onyx Pharmaceuticals' (NASDAQ: ONXX ) Kyprolis, which was approved last year as a treatment for multiple myeloma patients who had failed to respond, or stopped responding, to two previous treatments. The accelerated approval of Kyprolis was based on its overall response rate of 22.9%. While it delivered a median response duration of 7.8 months, it also came with a laundry list of side effects, with serious adverse events reported in a whopping 45% of patients.�
Top Electric Utility Stocks To Buy Right Now: KBB Resources Bhd (KBB)
KBB Resources Berhad is an investment holding company. The Company is engaged in manufacturing and marketing of all types of rice and sago sticks (vermicelli), sago starch and related products. The Company�� product includes Rice Vermicelli, Instant Noodle, Instant Bihun, Laksa and Sago. The Company�� subsidiaries include Kilang Bihun Bersatu Sdn Bhd, which is engaged in Manufacturing and marketing of all types of rice and sago sticks (vermicelli); Rasayang Food Industries Sdn Bhd, which is engaged in manufacturing and trading of beehoon and beehoon laksa; Bersatu Noodles Industries Sdn Bhd, which is engaged in manufacturing and trading of noodles and related products, and Bersatu Biotechnology (Johore) Sdn Bhd, which is engaged in manufacturing and marketing of all types of sago starch and related products. Advisors' Opinion:- [By Neha Marwah]
LMC Automotive expects the annualized rate to be 16.1 million, the best in six years. This is a decent improvement from last year�� November, when the industry reported 15.3 million as the adjusted annualized rate. In comparison, Kelley Blue Book (KBB) expects the November 2013 SAAR to be around 15.6 million, while Edmunds.com estimates it to be 15.7 million.
Top Electric Utility Stocks To Buy Right Now: 7 Days Group Holdings Limited(SVN)
7 Days Group Holdings Limited, through its subsidiaries, operates a chain of limited service economy hotels under the brand name of 7 Days Inn in China. The company provides accommodations and services primarily to business and leisure travelers. As of December 31, 2010, it operated 568 hotels in operation, including 247 managed hotels, with 56,410 hotel rooms in 89 cities, as well as 197 hotels with 19,345 hotel rooms under conversion. The company was founded in 2004 and is based in Guangzhou, China.
Advisors' Opinion:- [By Rich Duprey]
Chinese economy hotel chain 7 Days Group (NYSE: SVN ) announced today that the company's shareholders had approved the going-private proposal that was offered up on Feb. 28.�Approximately 88.3% of the hotel chain's shares voted on the proposal, and approximately 86% voted in favor of it.�
No comments:
Post a Comment